Haisco Pharmaceutical Group (002653) Q3 2026 earnings summary

Executive summary

• 9M revenue rose 50.61% YoY to ¥4.970bn, while attributable net income increased 314.01% to ¥1.376bn; BD income, drug sales and collaboration product sales supported growth.

• Q3 revenue grew 44.30% YoY; attributable net income advanced 207.26% to ¥525.25m.

• 9M operating cash flow reached ¥1.051bn, up 170.10% YoY.

Financial highlights

• 9M adjusted net income, excluding non-recurring items, was ¥1.265bn, up 263.22% YoY; Q3 adjusted net income was ¥512.9m, up 200.01%.

• 9M total costs and expenses were ¥3.640bn; R&D expense rose 67.98% to ¥911.1m and administrative expense increased 35.45% to ¥419.5m.

• Other income increased 349.02% to ¥122.5m, mainly due to industrial support funds from the Shannan Investment Promotion Bureau.

• 9M non-recurring gains totaled ¥111.4m, including ¥106.1m in government grants.

Segment performance

• Revenue growth was attributed to higher BD business income, continued growth in finished-drug sales, and increased collaboration product sales.

• BD-related collections contributed to higher cash receipts from product sales and services, which increased 41.59% YoY to ¥4.693bn in 9M.